BigHat Biosciences is a protein therapeutics company that develops an antibody design platform guided by artificial intelligence.
BigHat Biosciences has raised $75.0M in total funding. The most recent round was Series B. The last funding was announced in July 2022.
BigHat Biosciences's investors include Andreessen Horowitz, Gaingels, 8VC, Innovation Endeavors, S32.
BigHat Biosciences is headquartered in San Mateo, United States.
BigHat Biosciences is a protein therapeutics company that develops an antibody design platform guided by artificial intelligence.
BigHat Biosciences is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"BigHat Biosciences — Funding & Investors." VCBacked, July 20, 2022, https://www.vcbacked.co/company/bighat-biosciences. Accessed July 19, 2026.
VCBacked. (2022). BigHat Biosciences — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/bighat-biosciences
{{cite web |title=BigHat Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/bighat-biosciences |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated